press-releases

Nov 06, 2024, 16:45 ET CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, […]

Oct 17, 2024, 08:30 ET CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver

Sep 25, 2024, 08:00 ET – Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design – Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  – Protocol for Phase 3

Sep 04, 2024, 16:30 ET CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management’s participation in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 16:01 ET –         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis –         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design –         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 –         Webcast of Earnings Call

Aug 07, 2024, 16:30 ET CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August

May 21, 2024, 08:00 ET DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial  CUPERTINO, Calif., May 21, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute

May 13, 2024, 16:05 ET –         FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis –         Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31,